Allingham- Glaucoma, 7ed

423

Capítulo 28 • Principios de terapia médica basados en evidencias

35. Chung HJ, Hwang HB, Lee NY. The association between primary open- angle glaucoma and blood pressure: two aspects of hypertension and hypotension. Biomed Res Int . 2015;2015:827516. 36. Lee J, Choi J, Jeong D, Kim S, Kook MS. Relationship between day- time variability of blood pressure or ocular perfusion pressure and glaucomatous visual field progression. Am J Ophthalmol . 2015;160(3): 522-527.e1. 37. Bhorade AM. The monocular trial controversy: a critical review. Curr Opin Ophthalmol . 2009;20(2):104-109. 38. Realini TD. A prospective, randomized, investigator-masked evaluation of the monocular trial in ocular hypertension or open-angle glaucoma. Ophthalmology . 2009;116(7):1237-1242. 39. Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta- adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study. Am J Ophthalmol . 2000;130(4):441-453. 40. Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug deliv- ery. J Ocul Pharmacol Ther . 2016;32(2):67-82. 41. Kumar S, Karki R, Meena M, Prakash T, Rajeswari T, Goli D. Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment. J Adv Pharm Technol Res . 2011;2(3):192-194. 42. Taskar P, Tatke A, Majumdar S. Advances in the use of prodrugs for drug delivery to the eye. Expert Opin Drug Deliv . 2017;14(1):49-63. 43. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol . 2002;47(suppl 1):S34-S40. 44. Nagata A, Mishima HK, Kiuchi Y, Hirota A, Kurokawa T, Ishibashi S. Binding of antiglaucomatous drugs to synthetic melanin and their hypotensive effects on pigmented and nonpigmented rabbit eyes. Jpn J Ophthalmol . 1993;37(1):32-38. 45. Lee VH, Hui HW, Robinson JR. Corneal metabolism of pilocarpine in pigmented rabbits. Invest Ophthalmol Vis Sci . 1980;19(2):210-213. 46. March WF, Stewart RM, Mandell AI, Bruce LA. Duration of effect of pilo- carpine gel. Arch Ophthalmol . 1982;100(8):1270-1271. 47. Dohlman CH, Pavan-Langston D, Rose J. A new ocular insert device for continuous constant-rate delivery of medication to the eye. Ann Ophthalmol . 1972;4(10):823-832. 48. Sun J, Lei Y, Dai Z, et al. Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma. ACS Appl Mater Interfaces . 2017;9(9):7990-7999. 49. Sánchez-López E, Espina M, Doktorovova S, Souto EB, Garcí ML. Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye. Part I: Barriers and determining factors in ocular deliv- ery. Eur J Pharm Biopharm . 2017;110:70-75. 50. Sánchez-López E, Espina M, Doktorovova S, Souto EB, García ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part II – Ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm . 2017;110:58-69. 51. Joseph RR, Venkatraman SS. Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine (Lond) . 2017;12(6):683-702. 52. Camp A, Wellik SR, Tzu JH, et al. Dry eye specific quality of life in veter- ans using glaucoma drops. Cont Lens Anterior Eye . 2015;38(3):220-225. 53. Cvenkel B, Stunf S, Srebotnik Kirbis I, Strojan Flezar M. Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma. Clin Ophthalmol . 2015;9:625-631. 54. Goldberg I, Graham SL, Crowston JG, d’Mellow G, Australian and New Zealand Glaucoma Interest Group. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Exp Ophthalmol . 2015;43(3):214-220. 55. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol . 1997;41(suppl 2):S69-S75. 56. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of bri- monidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol . 1999;128(1):8-14. 57. Gill K, Bayart C, Desai R, Golden A, Raimer P, Tamburro J. Brimonidine toxicity secondary to topical use for an ulcerated hemangioma. Pediatr Dermatol . 2016;33(4):e232-e234. 58. Vanhaesebrouck S, Cossey V, Cosaert K, Allegaert K, Naulaers G. Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate. Eur J Ophthalmol . 2009;19(4): 694-695. 59. Lai Becker M, Huntington N, Woolf AD. Brimonidine tartrate poison- ing in children: frequency, trends, and use of naloxone as an antidote. Pediatrics . 2009;123(2):e305-e311.

60. Rangan C, Everson G, Cantrell FL. Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings. Pediatr Emerg Care . 2008;24(3):167-169. 61. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol . 2008;294(6):C1378-C1386. 62. Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol . 2014;8:883-890. 63. Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04%AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma . 2015;24(1):51-54. 64. Kiel JW, Kopczynski CC. Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther . 2015;31(3):146-151. 65. Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci . 2016;57(14):6197-6209. 66. Van de Velde S, De Groef L, Stalmans I, Moons L, Van Hove I. Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhib- itors as promising therapeutics. Prog Neurobiol . 2015;131:105-119. 67. Inazaki H, Kobayashi S, Anzai Y, et al. One-year efficacy of adjunctive use of ripasudil, a Rho-kinase inhibitor, in patients with glaucoma inade- quately controlled with maximummedical therapy. Graefes Arch Clin Exp Ophthalmol . 2017;255(10):2009-2015. 68. Kim CY, Park KH, Ahn J, et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol . 2017;101(6):801-807. 69. Osman EA, Alqarni BA, AlHasani SS, Al Harbi SS, Gikandi PW, Mousa A. Compliance of glaucoma patients to ocular hypotensive medications among the Saudi population. J Ocul Pharmacol Ther . 2016;32(1):50-54. 70. Rees G, Chong XL, Cheung CY, et al. Beliefs and adherence to glaucoma treatment: a comparison of patients from diverse cultures. J Glaucoma . 2014;23(5):293-298. 71. Pleet A, Sulewski M, Salowe RJ, et al. Risk factors associated with pro- gression to blindness from primary open-angle glaucoma in an African- American population. Ophthalmic Epidemiol . 2016;23(4):248-256. 72. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology . 2009;116(11 suppl):S30-S36. 73. Feehan M, Munger MA, Cooper DK, et al. Adherence to glaucoma med- ications over 12 months in two US community pharmacy chains. J Clin Med . 2016;5(9). pii:E79. Available at www.ncbi.nlm.nih.gov/pmc/articles/ PMC5039482. 74. Cook PF, Schmiege SJ, Mansberger SL, et al. Motivational interviewing or reminders for glaucoma medication adherence: results of a multi-site randomised controlled trial. Psychol Health . 2017;32(2):145-165. 75. Killeen OJ, MacKenzie C, Heisler M, Resnicow K, Lee PP, Newman-Casey PA. User-centered design of the eyeGuide: a tailored glaucoma behavior change program. J Glaucoma . 2016;25(10):815-821. 76. Stringham J, Ashkenazy N, Galor A, Wellik SR. Barriers to glaucoma medication compliance among veterans: dry eye symptoms and anxiety disorders. Eye Contact Lens . 2018;44(1):50-54. 77. Waisbourd M, Dhami H, Zhou C, et al. The Wills Eye Glaucoma app: interest of patients and their caregivers in a smartphone-based and tablet- based glaucoma application. J Glaucoma . 2016;25(9):e787-e791. 78. Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol . 2017;175:137-147. 79. Ellis PP, Wu PY, Pfoff DS, Bloedow DC, Riegel MR. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye. J Pharm Sci . 1992;81(3):219-220. 80. Larsson LI. Intraocular pressure over 24 hours after repeated administra- tion of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology . 2001;108(8):1439-1444. 81. Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol . 2009;20(2):79-83. 82. Querat L, Chen E. Monitoring daily intraocular pressure fluctuations with self-tonometry in healthy subjects. Acta Ophthalmol . 2017;95(5):525-529. 83. Sood V, Ramanathan US. Self-monitoring of intraocular pressure out- side of normal office hours using rebound tonometry: initial clini- cal experience in patients with normal tension glaucoma. J Glaucoma . 2016;25(10):807-811. 2 8 2

84. Dabasia PL, Lawrenson JG, Murdoch IE. Evaluation of a new rebound tonometer for self-measurement of intraocular pressure. Br J Ophthalmol . 2016;100(8):1139-1143. 85. Sethi HS, Naik M, Gupta VS. Management of glaucoma in pregnancy: risks or choices, a dilemma? Int J Ophthalmol . 2016;9(11):1684-1690. Sample 2 6